AR047237A1 - Composicion farmaceutica destinada a la admninistracion oral de un derivado de pirazol - Google Patents

Composicion farmaceutica destinada a la admninistracion oral de un derivado de pirazol

Info

Publication number
AR047237A1
AR047237A1 ARP040104109A ARP040104109A AR047237A1 AR 047237 A1 AR047237 A1 AR 047237A1 AR P040104109 A ARP040104109 A AR P040104109A AR P040104109 A ARP040104109 A AR P040104109A AR 047237 A1 AR047237 A1 AR 047237A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
carboxamide
derivative
oral
admninistration
Prior art date
Application number
ARP040104109A
Other languages
English (en)
Inventor
Thierry Breul
Jean-Claude Gautier
Olivier Saslawski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR047237A1 publication Critical patent/AR047237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Composicion farmacéutica en forma líquida o semisolida para la administracion oral de un derivado de pirasol-3-carboxamida seleccionado entre: N-piperidino-5-(4-bromofenil)-1-(2,4-diclorofenil)-4-etilpirazol-3-carboxamida y N- piperidino-5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metil-pirazol-3-carboxamida donde dicho derivado de pirazol-3- carboxamida es solubilizado en una mezcla que contiene uno o más solventes lipídicos del rerivado pirazol-3-carboxamida y un egente tensioactivo hidrofilo no ionico cuyo balance hidrofilo-lipofilo es superior a 10. Reivindicacion 2: Composicion farmacéutica de acuerdo con la reivindicacion 1 que contiene además un co-solvente anfifilo o una mezcla de co-solventes anfífilos.
ARP040104109A 2003-11-10 2004-11-08 Composicion farmaceutica destinada a la admninistracion oral de un derivado de pirazol AR047237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313259A FR2861992B1 (fr) 2003-11-10 2003-11-10 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.

Publications (1)

Publication Number Publication Date
AR047237A1 true AR047237A1 (es) 2006-01-11

Family

ID=34508418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104109A AR047237A1 (es) 2003-11-10 2004-11-08 Composicion farmaceutica destinada a la admninistracion oral de un derivado de pirazol

Country Status (28)

Country Link
US (2) US20060264469A1 (es)
EP (1) EP1691808B1 (es)
JP (1) JP4767171B2 (es)
KR (1) KR20060108668A (es)
CN (1) CN100528158C (es)
AR (1) AR047237A1 (es)
AT (1) ATE429227T1 (es)
AU (1) AU2004289086A1 (es)
BR (1) BRPI0416341A (es)
CA (1) CA2544413A1 (es)
CY (1) CY1110478T1 (es)
DE (1) DE602004020797D1 (es)
DK (1) DK1691808T3 (es)
ES (1) ES2325373T3 (es)
FR (1) FR2861992B1 (es)
HK (1) HK1102021A1 (es)
HR (1) HRP20090393T1 (es)
IL (1) IL175556A (es)
MA (1) MA28419B1 (es)
NO (1) NO20062609L (es)
NZ (1) NZ547763A (es)
PL (1) PL1691808T3 (es)
PT (1) PT1691808E (es)
RU (1) RU2321404C1 (es)
SI (1) SI1691808T1 (es)
TW (1) TWI280129B (es)
WO (1) WO2005046690A1 (es)
ZA (1) ZA200604451B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
PT2192893E (pt) * 2007-08-21 2015-11-09 Basilea Pharmaceutica Ag Composição antifúngica
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20130317117A1 (en) * 2010-11-24 2013-11-28 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059691A (en) * 1990-01-22 1991-10-22 American Cyanamid Company N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69426408T2 (de) * 1993-09-28 2001-07-12 Novartis Ag, Basel Herstellung von Weichgelatinekapseln
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
CA2283896A1 (en) * 1997-03-14 1998-09-24 Shintaro Ishikawa Novel pyrimidine derivative
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6617426B1 (en) * 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
JP2001151669A (ja) * 1999-11-24 2001-06-05 Nippon Kayaku Co Ltd 経口用自己乳化製剤
EP1712222A3 (en) * 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP2005523295A (ja) * 2002-03-01 2005-08-04 ノバガリ、ファルマ、エスアー 難溶性薬剤の自己乳化型薬物送達システム
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process

Also Published As

Publication number Publication date
SI1691808T1 (sl) 2009-10-31
HRP20090393T1 (en) 2009-08-31
EP1691808B1 (fr) 2009-04-22
FR2861992A1 (fr) 2005-05-13
NO20062609L (no) 2006-06-06
JP2007516960A (ja) 2007-06-28
WO2005046690A1 (fr) 2005-05-26
RU2321404C1 (ru) 2008-04-10
TW200524597A (en) 2005-08-01
ES2325373T3 (es) 2009-09-02
IL175556A0 (en) 2008-04-13
CY1110478T1 (el) 2015-04-29
DE602004020797D1 (de) 2009-06-04
CN1925856A (zh) 2007-03-07
TWI280129B (en) 2007-05-01
CA2544413A1 (fr) 2005-05-26
ZA200604451B (en) 2007-10-31
US20060264469A1 (en) 2006-11-23
FR2861992B1 (fr) 2007-07-20
AU2004289086A1 (en) 2005-05-26
DK1691808T3 (da) 2009-08-03
KR20060108668A (ko) 2006-10-18
US20090004261A1 (en) 2009-01-01
HK1102021A1 (en) 2007-11-02
NZ547763A (en) 2009-08-28
JP4767171B2 (ja) 2011-09-07
PL1691808T3 (pl) 2009-09-30
IL175556A (en) 2010-11-30
ATE429227T1 (de) 2009-05-15
EP1691808A1 (fr) 2006-08-23
RU2006120447A (ru) 2007-12-20
CN100528158C (zh) 2009-08-19
PT1691808E (pt) 2009-07-14
MA28419B1 (fr) 2007-02-01
BRPI0416341A (pt) 2007-02-27

Similar Documents

Publication Publication Date Title
CY1112523T1 (el) Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
RS50209B (sr) Derivati pirazolokarboksilne kiseline, njihova priprema, farmaceutske kompozicije sa sadržajem istih
CO4950527A1 (es) Composiciones farmaceuticas para administracion oral del n- piperidino-5-(4-clorofenil)-1-(2,4-diclorofenil)-4- metilpirazolo-3-carboxamida, de sus sales y de sus solvatos
AR054782A2 (es) Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico
MA29564B1 (fr) Formulation de 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile
JP2003522145A5 (es)
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
AR052252A1 (es) Formulaciones topicas de nepafenac
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
NO20083027L (no) Kontrollert frigivelses-fastformpreparat
PE20021017A1 (es) Composicion parenteral reconstituible
MA29775B1 (fr) Derives de pyrazolone
AR050103A1 (es) Composicion
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR047237A1 (es) Composicion farmaceutica destinada a la admninistracion oral de un derivado de pirazol
GT200300276A (es) Nuevo hemisulfato anhidro cristalino 1-[4(s)-azido-2(s), 3(r)-dihidroxi-4-(hidroximetil)-1(r)-ciclopentil] citosina utilcomo agente antiviral
JP2018083805A (ja) 水性眼科組成物
AR047279A1 (es) Composicion detergente liquida
CN106068122A (zh) 二丁基羟基甲苯的稳定化方法
PE20050699A1 (es) Sistemas emulsionantes que contienen derivados de azetidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure